Hunter syndrome is inherited in an X-linked recessive pattern, meaning the genetic mutation responsible sits on the X chromosome. Because boys have only one X chromosome (inherited from their mother), a single copy of the mutated gene is enough to cause the disease. Girls have two X chromosomes, so they would need mutations on both copies to be fully affected, which is extremely rare. This is why Hunter syndrome occurs almost exclusively in males.
The Gene Behind Hunter Syndrome
Hunter syndrome, formally called mucopolysaccharidosis type II (MPS II), is caused by mutations in a gene called IDS, located near the end of the X chromosome at a region known as Xq28. This gene provides instructions for making an enzyme that breaks down complex sugar molecules called glycosaminoglycans (GAGs). When the enzyme is absent or barely functional, these sugar molecules build up inside cells throughout the body, gradually damaging the heart, airways, liver, skeleton, and in severe cases, the brain.
How the X-Linked Pattern Works
Every child inherits one sex chromosome from each parent. Mothers always pass on an X, while fathers pass on either an X (producing a daughter) or a Y (producing a son). This creates a straightforward but important asymmetry for conditions carried on the X chromosome.
If a mother carries one normal copy of the IDS gene and one mutated copy, each pregnancy has a 50% chance of passing on the mutation. A son who inherits the mutated X has no second X chromosome to compensate, so he will develop Hunter syndrome. A daughter who inherits the mutated X still has her father’s normal X chromosome to fall back on, so she becomes a carrier but typically does not develop the disease.
One key detail: fathers cannot pass X-linked conditions to their sons. A father gives his Y chromosome to every son and his X chromosome to every daughter. So an affected man will not have affected sons, but all of his daughters will be carriers.
Odds for a Carrier Mother’s Children
For a woman confirmed to carry one mutated IDS gene, each pregnancy breaks down like this:
- Sons: 50% chance of inheriting the mutation and being affected, 50% chance of being unaffected
- Daughters: 50% chance of inheriting the mutation and becoming a carrier, 50% chance of inheriting neither mutation
These probabilities apply independently to every pregnancy. Having one affected son does not change the odds for the next child.
Cases Without Family History
Not every case of Hunter syndrome traces back to a carrier mother. The mutation can arise spontaneously in the egg cell or very early in embryonic development, meaning a boy can be diagnosed even when no one in the family has ever carried the gene. These spontaneous (de novo) mutations account for a meaningful share of new diagnoses. When a family has no prior history, genetic testing of the mother helps clarify whether she is a carrier or whether the mutation was a one-time event, which significantly changes the risk for future pregnancies.
Can Female Carriers Have Symptoms?
In most carrier women, the normal X chromosome produces enough working enzyme to prevent disease. But the body doesn’t use both X chromosomes equally in every cell. Early in development, each cell randomly shuts down one of its two X chromosomes, a process called X-inactivation. If, by chance, a disproportionate number of cells silence the normal X and rely on the mutated one, a carrier woman can start showing symptoms.
A Spanish study of 10 confirmed female carriers found that 6 had this skewed inactivation pattern. Three of them, aged 38, 42, and 52, had elevated GAG levels and recognizable Hunter syndrome features: skeletal abnormalities, hearing loss, recurrent ear infections, liver enlargement, and carpal tunnel syndrome. The oldest carrier, whose inactivation was most heavily skewed (86% of cells using the mutated X), had the most extensive symptoms, including bilateral deafness, lung problems, and significant skeletal changes. The findings suggest that symptoms in carrier women may be progressive and worsen with age, particularly when X-inactivation is heavily skewed toward the mutant copy.
These cases remain uncommon, but they highlight why carrier women benefit from periodic monitoring, especially as they get older.
How Carrier Status Is Identified
Enzyme activity testing, the standard method for diagnosing affected boys, is not reliable for identifying female carriers. A carrier woman’s cells produce a mix of working and non-working enzyme, so her overall enzyme levels can fall anywhere in the normal range. Genetic testing of the IDS gene itself is the only dependable way to determine whether a woman carries the mutation. This distinction matters enormously for family planning, since a confirmed carrier faces a 50% chance of having an affected son with each pregnancy.
Prenatal Testing Options
For families with a known history of Hunter syndrome, prenatal diagnosis is available as early as the 12th week of pregnancy. The preferred approach measures enzyme activity in a small sample of tissue from the placenta (chorionic villus sampling), which delivers results within two to three days. Testing can also be performed on amniotic fluid cells collected later in pregnancy. Over 30 years of accumulated data from one large center, covering 174 prenatal analyses, has shown these methods to be reliable. Twenty-seven affected male fetuses were identified through clearly abnormal enzyme levels.
Because very low enzyme activity has occasionally been measured in female fetuses who are carriers, prenatal enzyme testing is typically combined with determining the sex of the fetus to avoid misinterpreting results. Molecular genetic testing, which looks directly at the DNA sequence, can confirm or rule out the mutation with even greater precision and is increasingly available alongside enzyme-based methods.
Prevalence
Hunter syndrome is rare. Estimates place it at roughly 1 in 100,000 to 1 in 170,000 male births, though the exact figure varies by population and study. Because the condition is X-linked, prevalence statistics are calculated among boys. The handful of symptomatic female cases reported worldwide are considered sporadic exceptions rather than a meaningful share of overall diagnoses.